首页 > 市场调查报告书 > 製药

分子标靶治疗学

市场调查报告书

商品编码

1909205

全球 EZH2 标靶治疗市场：市场机会、已核准药物定价、销售及临床试验展望（至 2026 年）

Global EZH2 Targeted Therapy Market Opportunity, Approved Drug Price, Sales & Clinical Trials Insight 2026

出版日期: 2026年01月01日 | 出版商:

KuicK Research | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球 EZH2 标靶治疗市场 - 市场机会、已核准药物定价、销售及临床试验展望（至 2026 年）研究结果及亮点：

全球及区域市场趋势分析
已核准的 EZH2 标靶治疗药物数量：2
EZH2 标靶治疗药物有条件核准数量：1
已核准药物的剂量、价格及销售情况分析
按公司、国家、适应症及阶段划分的全球 EZH2 标靶治疗临床试验分析
主要标靶治疗药物的启动及完成年份分析
竞争格局

EZH2 标靶治疗的需求治疗方法及本报告的意义

抑制 EZH2（增强子 Zeste 同源物 2）是现代治疗的前沿，尤其是在血液肿瘤和实体瘤的治疗中。近年来，作为多梳抑制复合物 2 (PRC2) 的关键催化亚基，EZH2 的抑制已成为现代癌症治疗的主要标靶之一。 EZH2 抑制对錶观遗传修饰具有重要意义，特别是组蛋白 H3 第 27 位残基（称为 H3K27me3）的修饰，可抑制参与细胞分化、增殖或肿瘤抑制的基因表现。 EZH2 的异常活性，例如过度表现、突变或 PRC2 讯号传导异常，与包括实体瘤在内的多种白血病的发生髮展密切相关。因此，EZH2 已成为开发针对这些恶性肿瘤的潜在疗法的极具吸引力且经过生物学验证的标靶。本报告全面而深入地概述了EZH2标靶治疗策略的现状，涵盖了从小分子抑制剂到新一代表观遗传疗法和联合疗法等各个方面，可谓恰逢其时，意义重大。

本报告概述了目前的临床现状、技术发展、关键参与者和策略联盟，这些都表明EZH2抑制疗法是肿瘤学领域的下一个重大突破。报告强调了EZH2标靶疗法日益增长的重要性，并深入分析了其在革新癌症治疗方面的潜力，尤其针对那些存在EZH2失调或突变的癌症。随着创新加速发展，本报告是追踪未来几年将影响癌症治疗的最新进展的重要指南。

本报告涵盖的EZH2标靶疗法临床试验概况

本报告分析了EZH2标靶疗法的最新临床试验，并详细介绍了处于不同阶段的正在进行的试验。本报告探讨了这些试验的现状以及正在进行的试验中令人鼓舞的结果。临床活性已在多种癌症适应症中得到验证，包括滤泡性淋巴瘤、上皮样肉瘤、週边T细胞淋巴瘤和转移性前列腺癌。

本报告检视了多种EZH2抑制剂的疗效和安全性，包括Tazberic（tazemetostat）、zemetostat和mebrometostat，并在条件允许的情况下概述了患者的缓解率、无恶化存活期和总生存期结果。此外，本报告也指出了具有协同增效作用的治疗方案，例如将EZH2抑制剂与免疫检查点抑制剂和传统化疗药物合併使用的疗法。基于临床试验结果，本报告强调了EZH2抑製作为治疗方法的巨大潜力，并重点指出了未来最值得关注的创新领域。

积极参与 EZH2 标靶疗法研发的关键公司

多家大型公司正在推动 EZH2 标靶疗法的研发。本报告重点介绍并列出了积极从事 EZH2 标靶药物研发的关键公司。 Tazberic 的生产商 Epizyme（现为 Ipsen）是该领域的先驱，并持续扩大针对多种癌症类型的临床试验。其他公司，例如恆瑞製药的 zemetostat 和辉瑞的 mebrometostat，也在开髮用于治疗血液肿瘤和实体瘤的 EZH2 抑制剂方面取得了稳步进展。

本报告也探讨了新兴生技公司的研究趋势。例如，Treeline Biosciences 正在探索 EZH2 抑制的新作用机制，而韩美製药正在开发双重 EZH1/2 抑制剂 HM97662。这些公司正在探索多种方法，包括靶向 EZH2 的非酶活性以及开发选择性降解剂，以克服抗药性并提高 EZH2 抑制剂的治疗效果。本报告提供了全面的公司概况、旗舰专案和临床研究方法，为利害关係人提供了重要的见解。

一份重点介绍 EZH2 标靶疗法未来发展的报告

EZH2 标靶疗法的前景非常光明。本报告详细介绍了该领域的预期发展，包括针对各种癌症类型正在进行的 EZH2 抑制剂临床研究。随着更多生物标记得到验证并纳入临床决策，治疗将越来越个人化，从而改善患者的获益风险比。未来 EZH2 标靶疗法预计将涉及抑制剂、促进降解剂和其他旨在克服抗药性的新型策略的联合应用。

此外，新一代药物的出现，例如双重 EZH1/EZH2 抑制剂和选择性 EZH2 降解剂，有望提供更精准有效的治疗。本报告预测，策略联盟和合作关係的重要性将持续提升，推动创新并加速新型疗法的上市。随着技术的进步和新型药物研发管线的不断扩充，EZH2 抑制剂有望成为肿瘤治疗方案的重要组成部分，为患有难治性癌症的患者带来新的希望。

Global & Regional Market Trends Insight
Number Of Approved EZH2 Targeted Therapies: 2 Therapies
Conditional Approval To EZH2 Therapy: 1 Therapy
Approved Therapy Dosage, Price & Sales Insight
Global EZH2 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase
Key Therapies Initiation & Completion Year Insight
Competitive Landscape

Need For EZH2 Targeting Therapies & Why This Report

Inhibition of EZH2 (Enhancer of Zeste Homolog 2) has been at the forefront of contemporary therapy, especially for hematologic cancers and solid tumors. Inhibition of EZH2, an important catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), has recently become one of the primary areas being targeted in modern cancer treatment. Inhibiting EZH2 has significant implications in epigenetic modification, specifically in histone H3 at residue 27, known as H3K27me3, which represses gene expression involved in cell differentiation, proliferation, or suppressing tumors. Aberrant EZH2 activity, either via overexpression, mutation, or PRC2 signaling, has been extensively linked in the etiology of many different forms of leukemia, including solid cancers. Consequently, EZH2 has become an attractive, biologically proven target for developing potential medicines for these malignancies. The present report comes at a critical time and is greatly needed, as it presents a comprehensive and critical overview of current developments in EZH2 targeting strategies, ranging from small molecule inhibitors to next generation epigenetic and combination based approaches.

The report provides an overview of the present clinical landscape, technology developments, important players, and strategic collaborations that are making EZH2 inhibition in oncology the next big thing. It underscores the increasing significance of EZH2 targeted therapies, providing insights into how the treatments may revolutionize the treatment of cancers, especially those with dysregulation or mutations in EZH2. With innovation speeding up, this report is an essential guide to following developments that will likely influence cancer care over the next few years.

EZH2 Targeting Therapies Clinical Trials Insight Covered In Report

The report explores the most recent clinical trials of EZH2 Targeted therapies, providing in-depth insights into ongoing trials across various phases. It discusses not just the status of these trials as it stands now but also the encouraging outcomes coming from ongoing trials. Clinical activity is seen across a broad spectrum of cancer indications, such as follicular lymphoma, epithelioid sarcoma, peripheral T-cell lymphoma, and metastatic prostate cancer.

The report reviews the efficacy and safety profiles of different EZH2 inhibitors such as Tazverik (tazemetostat), Zemetostat, and Mevrometostat, giving an overview of patient response rates, progression free survival, and overall survival outcomes wherever possible. Moreover, the report identifies combination treatments, including those combining EZH2 inhibitors with immune checkpoint drugs or traditional chemotherapy drugs, with synergistic activities and increased therapeutic benefits. Based on clinical trial outcomes, the report identifies increasing optimism around EZH2 inhibition as a treatment approach as well as areas with the greatest potential for future innovations.

Leading Companies Active In R&D On EZH2 Targeting Therapies

Several key companies are driving the development of EZH2 targeting treatments forward. The report profiles and identifies the dominant players actively advancing EZH2 targeted drug development. Epizyme (Now Ipsen), the maker of Tazverik, is a trailblazer in the field and is continuing to grow its clinical trials in a variety of cancers. Other companies such as Hengrui Pharmaceuticals' Zemetostat and Pfizer's mevrometostat are also making good progress in developing EZH2 inhibitors for both hematologic and solid cancers.

The report also discusses the research of upcoming biotech companies such as Treeline Biosciences, which is exploring novel mechanisms of action for EZH2 inhibition, and Hanmi Pharmaceutical, which is developing the dual EZH1/2 inhibitor HM97662. These firms are pursuing varied approaches, such as targeting the non-enzymatic activities of EZH2 and developing selective degraders, to breach resistance and increase therapeutic effectiveness against EZH2 inhibition. The report offers comprehensive company profiles, lead programs, and clinical approaches, giving stakeholders important insights.

Report Indicating Future Development Of EZH2 Targeting Therapies

In the future, the prospects for EZH2 targeted therapies are very bright. The report details the anticipated course of the field, with sustained clinical investigation of EZH2 inhibitors in various cancers. The therapies will become progressively more personalized as more biomarkers are validated and incorporated into clinical decision making, enhancing the benefit risk profiles for patients. The future of EZH2 targeting is anticipated to involve a combination of inhibitors, degraders, and other new strategies designed to overcome resistance.

Besides, with the onset of next generation drugs such as dual EZH1/EZH2 inhibitors and selective EZH2 degraders, the area is set to provide more accurate and effective therapies. The report also predicts the growing significance of strategic collaborations and partnerships, which will keep on fueling innovation and taking new treatments to the market at a faster rate. As the technology advances and more new agents move into the pipeline, EZH2 inhibitors will become an important component of the oncology portfolio, bringing new hope to patients suffering with challenging and difficult to treat cancers.

1. Introduction To EZH2 Targeted Therapies

1.1 Overview Of EZH2 Targeted Therapies
1.2 Development & Evolution

2. Mechanistic Insights & Therapeutic Targeting Of EZH2

2.1 Small Molecule Inhibitors
- 2.1.1 Catalytic Inhibitors
- 2.1.2 Allosteric inhibitors
2.2 EZH2 Degraders
2.3 Gene Silencing

3. Global EZH2 Targeted Therapy Clinical Trials Overview

3.1 By Phase
3.2 By Country
3.3 By Company
3.4 By Indication

4. Tazverik - First Approved EZH2 Targeted Therapy

4.1 Overview, Availability & Patent Insight
4.2 Dosage & Price Analysis
4.3 Sales Analysis

5. Ezharmi - Second Approved EZH2 Targeted Therapy

6. Zeprumetostat (Conditional Approval September 2025)

7. Global EZH2 Targeted Therapy Market Analysis

7.1 Current Market Scenario
7.2 Future Market Opportunities

8. Global EZH2 Targeted Therapy Market Opportunity By Region

8.1 US
8.2 Europe
8.3 Japan
8.4 China
8.5 South Korea

9. EZH2 Role & Targeted Therapy Development Trends By Indication

9.1 Cancer
- 9.1.1 Solid Cancer
- 9.1.2 Hematologic Malignancies
9.2 Autoimmune & Inflammatory Diseases
9.3 Neurological Disorders
9.4 Others

10. Global EZH2 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

10.1 Preclinical
10.2 Phase I
10.3 Phase I/II
10.4 Phase III
10.5 Registered

11. Marketed EZH2 Targeting Therapy Clinical Trials Insight By Company, Country, Indication & Phase

12. Global EZH2 Targeted Therapy Market Dynamics

12.1 Market Drivers & Opportunities
12.2 Challenges & Strategic Solutions

13. Competitive Landscape

13.1 Axter Therapeutics
13.2 Daiichi Sankyo
13.3 Evopoint Biosciences
13.4 GSK
13.5 Haihe Biopharma
13.6 Hanmi Pharmaceutical
13.7 Ipsen
13.8 Jiangsu HengRui Medicine.
13.9 Novartis
13.10 Pfizer

简介目录图表

List of Figures

Figure 1-1: EZH2 - Functions & Relevance As Therapeutic Target
Figure 1-2: Dual Biological Role Of EZH2
Figure 1-3: EZH2 Inhibitors - Regulatory Milestones
Figure 1-4: EZH2 Inhibition - Resistance Mechanisms
Figure 1-5: Timeline Of EZH2 research & Drug Milestones
Figure 2-1: EZH2 Inhibition - Mechanistic Overview
Figure 2-2: Catalytic vs. Allosteric EZH2 Inhibition
Figure 2-3: EZH2 Degraders - Mechanism Of Action
Figure 2-4: EZH2 Degradation - Downstream Biological Consequences In Cancer
Figure 2-5: EZH2 Degradation - Therapeutic Rationale
Figure 2-6: Overview Of Gene Silencing Approaches Targeting EZH2
Figure 2-7: EZH2 Gene Silencing - Advantages In Cancer Therapy
Figure 3-1: Global - Number Of EZH2 Targeted Therapies In Clinical Trials By Phase, 2026
Figure 3-2: Global - Number Of EZH2 Targeting Therapies In Clinical Trials By Country, 2026
Figure 3-3: Global - Number Of EZH2 Targeting Therapies In Clinical Trials By Company, 2026
Figure 3-4: Global - Number Of EZH2 Targeting Therapies In Clinical Trials By Indication, 2026
Figure 4-1: Tazverik -Approval Year By Region
Figure 4-2: Tazverik - Patent Filing & Expiration Year
Figure 4-3: Tazverik - Price Per Unit & Supply (US$), January'2026
Figure 4-4: Tazverik - Recommended Initial & Reduced Dose (mg/Twice Daily)
Figure 4-5: Tazverik - Cost Monthly & Annual Treatment (US$), January'2026
Figure 4-6: Global - Tazverik Annual Sales (US$ Million), 2022-2025
Figure 4-7: Global - Tazverik Quarterly Sales (US$ Million), Q1-Q3'2025
Figure 4-8: Global - Tazverik Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 7-1: EZH2 Targeted Therapy Market - Future Opportunities
Figure 9-1: EZH2 - Cancer Hallmarks
Figure 9-2: EZH2 - Canonical vs Non-Canonical Functions
Figure 9-3: EPZ-IST-001 Phase 2 (NCT05023655) Study - Initiation & Completion Year
Figure 9-4: 22 041 Phase 1 (NCT04846478) Study - Initiation & Completion Year
Figure 9-5: EZH-1201 Phase 1 (NCT04241835) Study - Initiation & Completion Year
Figure 9-6: CHN-PLAGH-BT-055 Phase 1/2 (NCT04407741) Study - Initiation & Completion Year
Figure 9-7: SPLP-002-21F Phase 1/2 (NCT05467748) Study - Initiation & Completion Year
Figure 9-8: EZH2 - Overview In Hematologic Malignancies
Figure 9-9: Hematologic Malignancies - Approved EZH2 Targeting Drugs
Figure 9-10: 22-07025095 Phase 1 (NCT05934838) Study - Initiation & Completion Year
Figure 9-11: 23-06026184 Phase 2 (NCT05994235) Study - Initiation & Completion Year
Figure 9-12: CLIN-60200-452 Phase 2 (NCT06068881) Study - Initiation & Completion Year
Figure 9-13: NCI-2022-05327 Phase 1 (NCT05627245) Study - Initiation & Completion Year
Figure 9-14: PTCL-IIT-SHR2554-SHR0302 Phase 2 (NCT06519526) Study - Initiation & Completion Year
Figure 9-15: EZH2 - Roles Across Immune Cells
Figure 9-16: EZH2 In Autoimmune & Inflammatory Diseases
Figure 12-1: EZH2 Targeted Therapy Market - Drivers & Opportunities
Figure 12-2: EZH2 Targeted Therapy Market - Challenges & Strategic Solutions

List of Tables

Table 2-1: EZH2 Degraders - Classification
Table 2-2: EZH2 Gene Silencing - Challenges & Solutions In Clinical Translation

Table 5 -: Ezharmia - Key Points

Table 6-1: Zeprumetostat - Key Points
Table 9-1: EZH2 - Involvement In Neurological Diseases

02-2729-4219

+886-2-2729-4219

License/价格

全球 EZH2 标靶治疗市场：市场机会、已核准药物定价、销售及临床试验展望（至 2026 年）

Global EZH2 Targeted Therapy Market Opportunity, Approved Drug Price, Sales & Clinical Trials Insight 2026

目录

第一章：EZH2标靶治疗简介

第二章：EZH2机制解析与治疗标靶

第三章：EZH2标靶治疗临床试验的全球概览

第四章：Tazveric－首个核准的 EZH2 标靶治疗药物

第五章：Ezharmi－第二个核准的 EZH2 标靶治疗药物

第六章：Zepulmetostat（有条件批准，2025 年 9 月）

第七章：全球 EZH2 标靶治疗药物市场分析

第八章：EZH2 标靶治疗药物市场机会（按地区划分）

第九章 EZH2 的作用及标靶治疗发展趋势（依适应症划分）

第十章 EZH2 标靶治疗临床试验的全球概况（按公司、国家、适应症和阶段划分）

第十一章 EZH2 的商业化临床试验标靶治疗：按公司、国家、适应症和阶段划分

第十二章全球 EZH2 标靶治疗市场动态

第十三章竞争格局

Table of Contents